Sinovac Biotech Holds 2007 Annual General Meeting

  • Author: 佚名
  • Date: 2008-09-19
  • Source: 本站原创
  • Pageview: 7950

Sinovac Biotech Holds 2007 Annual General Meeting
Thursday September 18, 8:00 am ET

BEIJING, Sept. 18 /Xinhua-PRNewswire/ --  Sinovac Biotech Ltd. (Amex: SVA - News), a leading provider of vaccines in China, today announced that its Annual General Meeting originally scheduled for September 4, 2008 was held two weeks later, on September 18, 2008.

 

During the September 18, Annual General Meeting, held at Sinovac's headquarters located at No. 39, Shangdi Xi Rd., Haidian District, Beijing, PRC, the Company's 2007 Annual Report was reviewed, and the appointment of Ernst & Young as Sinovac's registered public accountants was approved.

 

About Sinovac

 

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive® (hepatitis A), Bilive® (combined hepatitis A and B), Anflu® (influenza) and Panflu(TM)(H5N1). Sinovac is currently developing Universal Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional information about Sinovac is available on its website, http://www.sinovac.com . To be added to our distribution list, please email: info@sinovac.com.

 

 

 

For more information, please contact:

 

Helen G. Yang

 

Sinovac Biotech Ltd.

 

Tel:   +86-10-8289-0088 x871

 

Fax:   +86-10-6296-6910

 

Email: info@sinovac.com

 

Investors/Media:

 

Stephanie Carrington/Janine McCargo

 

The Ruth Group

 

Tel:   +1-646-536-7017/7033

 

Email: scarrington@theruthgroup.com

 

      jmccargo@theruthgroup.com

 

Bookmark and Share

Copyright © 2001-2015 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085 Supported by elongtian